Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma
Edwina Coghlan, Paul A. Cohen(The University of Western Australia), Colin J.R. Stewart(King Edward Memorial Hospital), Cassandra Nichols(Peter MacCallum Cancer Centre), Daniel Magee(Caris Life Sciences (United States)), Aime Munro(St John of God Subiaco Hospital), Adeline Tan(Albert Einstein College of Medicine), Jim Codde(The University of Notre Dame Australia), Tarek Meniawy(St John of God Subiaco Hospital), Yee Leung(King Edward Memorial Hospital), MH Eleanor Koay(King Edward Memorial Hospital), Jason Tan(St John of God Subiaco Hospital), Stuart Salfinger(St John of God Subiaco Hospital), Ganendra Raj Mohan(St John of God Subiaco Hospital), Max Bulsara(The University of Notre Dame Australia)
Cited by 51
Related Papers
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
The quanitification of drug caused morbidity and mortality in Australia: Part 1
|UWA Profiles and Research Repository (University of Western Australia)|1995|470
RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes
|Journal of the American Society of Nephrology|2009|461